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ABSTRACT 
The spirocyclic ring structure is a feature of a number of naturally-occurring and 
synthetic products that possess interesting biologically activities. This thesis describes 
our efforts towards synthesising various spirocyclic heterocycles as potential cancer 
therapeutics targeting the cell-cycle. Three different spirocyclic scaffolds, A-C, were 
accessed through a variety of cycloaddition reactions and several of these were 
investigated for their cytostaticity and protein-inhibition properties. To gain further 
insights into the development of novel CDK2 inhibitors, part of this research was 
conducted at the Anti-Cancer Drug Design Initiative (ADDI) laboratory, University of 
Newcastle upon the Tyne, UK.  
This thesis is divided into three primary synthetic chemistry chapters, based upon 
discussion surrounding the main chemistries used to derive the various spirocyclic 
oxindole scaffolds of the types A-C. Chapter 2 describes the use of the phosphine-
catalysed [3+2]-cycloaddition reaction to synthesise racemic and enantio-enriched 
versions of spirocycles of type A. Chapter 3 describes the use of the cyclopropanation 
reaction to synthesise spirocycles of type B. Lastly, Chapter 4 describes the 
employment of the [1,3]-dipolar cycloaddition reaction of nitrones to the synthesis of 
spirocycles of type C. A discussion on the CDK2 research, performed in the UK, 
towards a new synthetic strategy employing directed ortho metalation chemistry is then 
provided in Chapter 5. The cellular cytostaticity screening against the cancer cell lines, 
H460, MCF-7 and SF-268, and protein inhibition studies against the cell-cycle proteins 
CDK2, CDK5, gSK-3 and MDM2, for a range of the spirocycles synthesised in 
Chapters 2-4, is then given and discussed in Chapter 6. Final conclusions and future 
work are drawn together in Chapter 7. All synthetic methods and physical and 
spectroscopic data are provided for all compounds in Chapter 8. Lastly, an appendix 
including all X-ray crystal structures and their crystallographic data, and also a section 
on the biological testing procedures is provided. 
 
